Difference between revisions of "ICRP Glossary"

From ICRPaedia
Jump to navigation Jump to search
(29 intermediate revisions by the same user not shown)
Line 15: Line 15:
 
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
 
Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.
  
−
The ICRP Glossary shown here comprises some 400 terms. Entries for an additional approximately 400 terms are being prepared, and will be added here in due course.
+
The ICRP Glossary shown here comprises some 400 terms. Entries for an additional approximately 400 terms are being added progressively.
  
 
----
 
----
 
{| class="wikitable"
 
{| class="wikitable"
 
|-
 
|-
−
| [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]]
+
| [[#A|A]] || [[#B|B]]  || [[#C|C]]|| [[#D|D]] || [[#E|E]] || [[#F|F]] || [[#G|G]] || [[#H|H]] || [[#I|I]] || [[#J|J]] || [[#K|K]] || [[#L|L]] || [[#M|M]] ||[[#N|N]] || [[#O|O]] || [[#P|P]] || [[#Q|Q]] || [[#R|R]] || [[#S|S]] || [[#T|T]] || [[#U|U]] || [[#V|V]] || [[#W|W]] || [[#X|X]] || [[#Y|Y]] || [[#Z|Z]] || [[#ZZ|...]]
 
|}
 
|}
  
Line 33: Line 33:
 
*[[Acceptance test]]
 
*[[Acceptance test]]
  
−
*[[Access Control]]
+
*[[Access control]]
  
 
*[[Accountability]]
 
*[[Accountability]]
Line 43: Line 43:
 
*[[Activity median thermodynamic diameter]]
 
*[[Activity median thermodynamic diameter]]
  
−
*[[Acute Exposure]]
+
*[[Acute exposure]]
 +
 
 +
*Acute radiation sickness (see *[[Acute radiation syndrome]])
  
 
*[[Acute radiation syndrome]]
 
*[[Acute radiation syndrome]]
Line 53: Line 55:
 
*[[Adventitious]]
 
*[[Adventitious]]
  
−
*[[Adventitious Source]]
+
*[[Adventitious source]]
  
 
*[[Aerodynamic diameter ]]
 
*[[Aerodynamic diameter ]]
Line 70: Line 72:
  
 
*[[Alpha decay]]
 
*[[Alpha decay]]
−
 
−
*[[α/β ratio]]
 
  
 
*[[Alveolar-interstitial region]]
 
*[[Alveolar-interstitial region]]
Line 82: Line 82:
  
 
*[[Area monitoring]]
 
*[[Area monitoring]]
 +
 +
*ARS (see [[Acute radiation syndrome]])
  
 
*[[Attributable risk]]
 
*[[Attributable risk]]
Line 87: Line 89:
 
*[[Auger transition]]
 
*[[Auger transition]]
  
−
*[[Authorised Discharge]]
+
*[[Authorised discharge]]
  
 
*[[Authorization]]
 
*[[Authorization]]
Line 103: Line 105:
 
*[[Background dose (rate)]]
 
*[[Background dose (rate)]]
  
−
*[[Backscatter Factor ]]
+
*[[Backscatter factor]]
  
 
*[[Basal cell]]
 
*[[Basal cell]]
  
 
*[[Baseline disease rates]]
 
*[[Baseline disease rates]]
 +
 +
*BAT (see [[Best available techniques]])
  
 
*[[Beneficence]]
 
*[[Beneficence]]
Line 113: Line 117:
 
*[[Benthic]]
 
*[[Benthic]]
  
−
*[[Best Available Techniques]]
+
*[[Best available techniques]]
  
 
*[[Beta-minus decay]]
 
*[[Beta-minus decay]]
Line 198: Line 202:
  
 
=== <big><span id="D">D</span></big> ===
 
=== <big><span id="D">D</span></big> ===
 +
 +
*DD (see [[Doubling dose)]])
 +
 +
*DDREF (see [[Dose and dose-rate effectiveness factor)]])
  
 
*[[Decay constant]]
 
*[[Decay constant]]
Line 211: Line 219:
 
*[[Deterministic effect]]
 
*[[Deterministic effect]]
  
−
*[[Detriment]]
+
*Detriment (see [[Radiation detriment]])
  
 
*[[Detriment-adjusted risk]]
 
*[[Detriment-adjusted risk]]
Line 229: Line 237:
 
*[[Disposal]]
 
*[[Disposal]]
  
−
*[[Disposal Facility]]
+
*[[Disposal facility]]
  
 
*[[DNA damage signalling]]
 
*[[DNA damage signalling]]
  
−
*[[Dose and dose-rate effectiveness factor (DDREF)]]
+
*[[Dose and dose-rate effectiveness factor)]]
  
 
*[[Dose constraint]]
 
*[[Dose constraint]]
Line 243: Line 251:
 
*[[Dose limit]]
 
*[[Dose limit]]
  
−
*[[Dose Modifying Factor]]
+
*[[Dose modifying factor]]
  
 
*[[Dose per unit intake coefficient]]
 
*[[Dose per unit intake coefficient]]
Line 268: Line 276:
  
 
*[[Effect Dose 50 ]]
 
*[[Effect Dose 50 ]]
 +
 +
*[[Effect modifier]]
  
 
*[[Effective charge number]]
 
*[[Effective charge number]]
Line 278: Line 288:
  
 
*[[Electrophysiology]]
 
*[[Electrophysiology]]
 +
 +
*[[Elemental dose]]
 +
 +
*ELR (see *[[Excess lifetime risk]])
  
 
*[[Emergency]]
 
*[[Emergency]]
Line 290: Line 304:
  
 
*[[Endogeneous excretion]]
 
*[[Endogeneous excretion]]
 +
 +
*[[Epigenetic effects]]
  
 
*[[Environmental exposure]]
 
*[[Environmental exposure]]
Line 304: Line 320:
  
 
*[[Ethics]]
 
*[[Ethics]]
 +
 +
*[[Excess absolute risk]]
 +
 +
*[[Excess lifetime risk]]
 +
 +
*[[Excess relative risk]]
  
 
*[[Excretion rate (instantaneous)]]
 
*[[Excretion rate (instantaneous)]]
Line 317: Line 339:
 
*[[Exposure, external or internal]]
 
*[[Exposure, external or internal]]
  
−
*[[Exposure Pathway]]
+
*[[Exposure pathway]]
  
 
*[[Exposure situation]]
 
*[[Exposure situation]]
Line 346: Line 368:
  
 
*[[Gastrointestinal syndrome]]
 
*[[Gastrointestinal syndrome]]
 +
 +
*[[Genomic integrity]]
  
 
*[[Graded approach]]
 
*[[Graded approach]]
Line 370: Line 394:
  
 
*[[Heliosphere]]
 
*[[Heliosphere]]
 +
 +
*[[Hereditary effect]]
  
 
*[[Hierarchical tissues]]
 
*[[Hierarchical tissues]]
  
 
*[[High level waste]]
 
*[[High level waste]]
 +
 +
*[[Homologous recombination]]
  
 
*[[Hormones]]
 
*[[Hormones]]
Line 390: Line 418:
  
 
*[[In vivo radiobioassay]]
 
*[[In vivo radiobioassay]]
 +
 +
*[[Incidence]]
 +
 +
*Incidence rate (see [[Incidence]])
  
 
*[[Incident]]
 
*[[Incident]]
Line 401: Line 433:
 
*[[Individual-related]]
 
*[[Individual-related]]
  
−
*[[Informed Consent]]
+
*[[Induced genomic instability]]
 +
 
 +
*[[Informed consent]]
  
 
*[[Inhalability]]
 
*[[Inhalability]]
Line 441: Line 475:
 
=== <big><span id="L">L</span></big> ===
 
=== <big><span id="L">L</span></big> ===
  
 +
*[[Late normal tissue responses]]
  
 
*[[Latent time/period or latency interval]]
 
*[[Latent time/period or latency interval]]
 +
 +
*[[LD 50/30|LD<sub>50/30</sub>]]
 +
 +
*[[Life span study]]
 +
 +
*[[Lifetime risk]]
 +
 +
*[[Lifetime risk estimate]]
  
 
*[[Limitation of dose]]
 
*[[Limitation of dose]]
  
 
*[[Lineal energy]]
 
*[[Lineal energy]]
 +
 +
*[[Linear dose response]]
  
 
*[[Linear-non-threshold model]]
 
*[[Linear-non-threshold model]]
 +
 +
*[[Linear-quadratic dose response]]
 +
 +
*LLE (see [[Loss of Life Expectancy]])
 +
 +
*[[Loss of Life Expectancy]]
  
 
*[[Low Earth orbit]]
 
*[[Low Earth orbit]]
 +
 +
*[[Low dose]]
 +
 +
*[[Low dose rate]]
  
 
*[[Low level waste]]
 
*[[Low level waste]]
 +
 +
*LSS (see [[Life span study]])
  
 
*[[Lymphatic system]]
 
*[[Lymphatic system]]
  
 
=== <big><span id="M">M</span></big> ===
 
=== <big><span id="M">M</span></big> ===
−
 
  
 
*[[Macrophage colony stimulating factor]]
 
*[[Macrophage colony stimulating factor]]
Line 470: Line 526:
  
 
*[[Mitigation]]
 
*[[Mitigation]]
 +
 +
*[[Multiplicative risk projection model]]
 +
 +
*[[Multistage carcinogenesis model]]
  
 
*[[Multistage tumorigenesis]]
 
*[[Multistage tumorigenesis]]
 +
 +
*[[Mutation component]]
  
 
*[[Myocardial perfusion]]
 
*[[Myocardial perfusion]]
Line 486: Line 548:
  
 
*[[Neurovascular syndrome]]
 
*[[Neurovascular syndrome]]
 +
 +
*NHEJ (see [[Non-homologous end joining]])
 +
 +
*[[Nominal risk coefficient]]
 +
 +
*[[Non-homologous end joining]]
  
 
*[[Non-maleficence]]
 
*[[Non-maleficence]]
  
 
*[[Non-sphericity parameter]]
 
*[[Non-sphericity parameter]]
 +
 +
*[[Non-targeted effects]]
 +
 +
*[[Normal tissue complication probability]]
  
 
*[[Nuclear track detectors]]
 
*[[Nuclear track detectors]]
Line 495: Line 567:
 
=== <big><span id="O">O</span></big> ===
 
=== <big><span id="O">O</span></big> ===
  
 +
*[[Occupational exposure]]
  
−
*[[Occupational exposure]]
+
*[[Oncogene]]
  
 
*[[Optimisation]]
 
*[[Optimisation]]
Line 523: Line 596:
  
 
*[[Platelet-derived growth factor]]
 
*[[Platelet-derived growth factor]]
 +
 +
*PLDR (see [[Potentially lethal damage repair]])
 +
 +
*[[Pooled analysis]]
 +
 +
*[[Population risk]]
  
 
*[[Potential exposure]]
 
*[[Potential exposure]]
 +
 +
*[[Potentially lethal damage repair]]
  
 
*[[Practical radiological protection culture]]
 
*[[Practical radiological protection culture]]
Line 556: Line 637:
 
=== <big><span id="Q">Q</span></big> ===
 
=== <big><span id="Q">Q</span></big> ===
  
 +
*[[Qualified expert]]
  
−
*[[Qualified expert]]
+
*[[Quasi-threshold dose]]
  
 
=== <big><span id="R">R</span></big> ===
 
=== <big><span id="R">R</span></big> ===
Line 566: Line 648:
  
 
*[[Radiation modifier]]
 
*[[Radiation modifier]]
 +
 +
*[[Radiation risk]]
  
 
*[[Radiation safety officer]]
 
*[[Radiation safety officer]]
Line 585: Line 669:
 
*[[Radiographer]]
 
*[[Radiographer]]
  
−
*[[Radiological Controlled Area]]
+
*[[Radiological controlled area]]
  
 
*[[Radiological protection principles]]
 
*[[Radiological protection principles]]
Line 596: Line 680:
  
 
*[[Radiosensitivity, cellular]]
 
*[[Radiosensitivity, cellular]]
 +
 +
*RAP (see [[Reference Animal and Plant]])
 +
 +
*RBE (see [[Relative biological effectiveness]])
 +
 +
*[[Reactive oxygen species]]
  
 
*[[Reasonableness]]
 
*[[Reasonableness]]
Line 602: Line 692:
  
 
*[[Recovery responder]]
 
*[[Recovery responder]]
 +
 +
*[[Recovery (cellular or tissue)]]
 +
 +
*[[Reference Animal and Plant]]
  
 
*[[Reference bioassay function]]
 
*[[Reference bioassay function]]
Line 608: Line 702:
  
 
*[[Reference level]]
 
*[[Reference level]]
 +
 +
*REID (see [[Risk of exposure-induced death]])
  
 
*[[Rehabilitation of living conditions]]
 
*[[Rehabilitation of living conditions]]
 +
 +
*[[Relative biological effectiveness]]
 +
 +
*[[Relative life lost]]
 +
 +
*[[Relative risk]]
  
 
*[[Relocation]]
 
*[[Relocation]]
Line 638: Line 740:
  
 
*[[Rigidity]]
 
*[[Rigidity]]
 +
 +
*[[Ring chromosome]]
 +
 +
*[[Risk]]
 +
 +
*[[Risk coefficient]]
 +
 +
*[[Risk model]]
 +
 +
*[[Risk of exposure-induced death]]
 +
 +
*ROS (see [[Reactive oxygen species]])
  
 
*[[Routine monitoring]]
 
*[[Routine monitoring]]
 +
 +
*RR (see [[Relative risk]])
  
 
=== <big><span id="S">S</span></big> ===
 
=== <big><span id="S">S</span></big> ===
Line 652: Line 768:
  
 
*[[Senescence]]
 
*[[Senescence]]
 +
 +
*[[Severe deterministic injury]]
 +
 +
*SLDR (see [[Sublethal damage repair]])
  
 
*[[Slow repair]]
 
*[[Slow repair]]
Line 662: Line 782:
  
 
*[[Solar wind]]
 
*[[Solar wind]]
 +
 +
*[[Somatic effect]]
  
 
*[[Source term]]
 
*[[Source term]]
Line 676: Line 798:
  
 
*[[Stenosis]]
 
*[[Stenosis]]
 +
 +
*[[Stochastic effect]]
  
 
*[[Storage]]
 
*[[Storage]]
  
 
*[[Subcutaneous tissue]]
 
*[[Subcutaneous tissue]]
 +
 +
*[[Sublethal damage repair]]
  
 
*[[Substantial radiation dose level]]
 
*[[Substantial radiation dose level]]
  
−
*[[Supervised Area]]
+
*[[Supervised area]]
  
 
*[[Systemic model]]
 
*[[Systemic model]]
Line 695: Line 821:
  
 
*[[Target tissue]]
 
*[[Target tissue]]
 +
 +
*[[Targeted effects]]
  
 
*[[Telangiectasia]]
 
*[[Telangiectasia]]
Line 705: Line 833:
  
 
*[[Tissue equivalent material]]
 
*[[Tissue equivalent material]]
 +
 +
*[[Tissue reaction]]
 +
 +
*[[Tissue weighting factor]]
  
 
*[[Tolerability]]
 
*[[Tolerability]]
Line 711: Line 843:
  
 
*[[Transfer compartment]]
 
*[[Transfer compartment]]
 +
 +
*[[Transfer of risk]]
  
 
*[[Transfer rate]]
 
*[[Transfer rate]]
  
 
*[[Transforming growth factor]]
 
*[[Transforming growth factor]]
 +
 +
*[[Transgenerational effect]]
 +
 +
*[[Translocation]]
  
 
*[[Transparency]]
 
*[[Transparency]]
 +
 +
*Transport of risk (see [[Transfer of risk]])
 +
 +
*[[Tumour suppressor gene]]
  
 
*[[Trapped particles]]
 
*[[Trapped particles]]
Line 723: Line 865:
  
 
=== <big><span id="U">U</span></big> ===
 
=== <big><span id="U">U</span></big> ===
−
 
  
 
*[[Unsealed source]]
 
*[[Unsealed source]]
Line 730: Line 871:
  
 
=== <big><span id="V">V</span></big> ===
 
=== <big><span id="V">V</span></big> ===
−
 
  
 
*[[Value judgement]]
 
*[[Value judgement]]
Line 743: Line 883:
  
 
*[[Wisdom]]
 
*[[Wisdom]]
 +
 +
*w<sub>T</sub> (see [[Tissue weighting factor]])
 +
 +
*w<sub>R</sub> (see [[Radiation weighting factor]])
  
 
=== <big><span id="X">X</span></big> ===
 
=== <big><span id="X">X</span></big> ===
Line 753: Line 897:
  
 
=== <big><span id="Z">Z</span></big> ===
 
=== <big><span id="Z">Z</span></big> ===
 +
 +
=== <big><span id="ZZ">...</span></big> ===
 +
 +
 +
*[[α/β value]]
 +
 +
*α/β ratio (see [[α/β value]])
 +
 +
*[[γH2AX foci]]
  
 
<div>
 
<div>

Revision as of 22:10, 24 February 2021

Glossary Header-left2.png





The ICRP Glossary collects ICRP’s definitive explanations of terms for current use. It is a living document, updated regularly. Each entry shows the date it was last updated, and some include past glossary entries to help readers better understand the term in a particular context.

Many ICRP publications have included their own glossaries. The ICRP Glossary includes most of the terms in these other glossaries, many with updated entries. ICRP publications will continue to have their own glossaries when necessary, for example for highly specialized terms relevant to a single publication or helpful for a reader to have close at hand, or when introducing a new term which would also be added to the ICRP Glossary.

Although the ICRP Glossary is not a dictionary, terms already well covered in the Oxford English Dictionary are not included here unless further explanation is needed to understand the way in which these terms are used in ICRP publications.

The ICRP Glossary shown here comprises some 400 terms. Entries for an additional approximately 400 terms are being added progressively.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ...

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

...

Retrieved from "http://icrpaedia.org/index.php?title=ICRP_Glossary&oldid=2720"